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Abstract
Background: Neuroinflammation—astrogliosis, microglial activation, and changes in cytokine signaling—is a
prominent feature of neurodegenerative disorders. Glaucoma is a group of chronic neurodegenerative conditions
that make up the leading cause of irreversible blindness worldwide. Neuroinflammation has been postulated to
play a significant role in the pathogenesis and progression of glaucomatous neurodegeneration. Though much is
known regarding inflammation in the eye in glaucoma, little is known about cytokine activity outside of the retina
where pathologies develop early.
Methods: We traced the primary visual projection from the eye to the superior colliculus (SC) in DBA/2J and
DBA/2J.Gpnmb+ (control) mice using the anterograde tracer cholera toxin-B (CTB) to assay axonal transport deficits.
Forty-eight hours later, visual structures were microdissected from fresh tissue based on transport outcome. Using
magnetic bead multiplexing assays, we measured levels of 20 cytokines in the retina, proximal and distal optic
nerves, CTB-positive and negative SC subdivisions, cerebellum, and serum at different ages representing different
stages of pathology.
Results: Pro- and anti-inflammatory cytokine levels in mice often changed in the same direction based on strain,
age, and tissue. Significant elevations in retinal pro-inflammatory cytokines were observed in young DBA/2J mice
compared to controls, followed by an age-dependent decrease in the DBA/2J mice. Proximal optic nerve of young
DBA/2J mice showed a 50 % or greater decrease in levels of certain cytokines compared to older DBA/2J cohorts
and controls, while both proximal and distal optic nerve of DBA/2Js showed elevations in IL-1β at all ages
compared to controls. Pro-inflammatory cytokine IL-6 levels varied in accordance with transport outcome in the SC:
IL-6 was elevated 44–80 % in glaucomatous DBA/2J collicular regions deficient in anterograde transport from retinal
ganglion cells (RGCs) compared to areas with intact transport.
Conclusion: Dysregulation of cytokine signaling in the RGC projection of DBA/2J mice was evident early in distal
retinal targets, well before intraocular pressure elevation or axonal degeneration begins.
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Background
Defects in axonal transport have been reported among
the earliest pathologies in many neurodegenerative dis-
orders [1, 2], including glaucoma [3–6]. Anterograde
transport deficits have been found to precede retrograde
deficits and overt structural degeneration of retinal gan-
glion cell (RGC) axons [7], indicating that an intact and
semi-functional axon persists after initial onset of path-
ology. Furthermore, astrogliosis occurs in the superior
colliculus (SC) after transport deficits but before axon
loss [8]. Given the early appearances of axon transport
deficits and neuroinflammation, obvious questions con-
cern the relationship between these two processes. While
much has been reported on inflammation in the retina
and optic nerve head, details of immune dysfunction such
as changes in cytokine levels have not been examined fur-
ther along the retinal projection—an area where we first
see transport deficits and degeneration [4, 9, 10].
Glaucomatous neurodegeneration is predicted to afflict
nearly 80 million people worldwide by the year 2020
[11]. Age and elevated intraocular pressure (IOP) are
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major risk factors for glaucoma, with IOP currently
comprising the only target of FDA-approved drug treat-
ments. However, what actually blinds in the disease is
the dysfunction and degeneration of RGCs [12, 13].
Also, given the common incidence of elevated IOP with-
out glaucomatous vision loss as well as normal tension
glaucoma, it is clear that many other factors play a role
in the development and progression of this degenerative
disease [14–16]. Abnormal activation of the immune sys-
tem has been shown to produce glaucomatous pathology
in the absence of elevated IOP [14]. Bosco and colleagues
have shown microglial activation within young DBA/2J
mouse retina, pre-laminar optic nerve, and nerve head
[17, 18], which suggests a role for immunomodulatory
molecules such as cytokines early in pathology in moder-
ately elevated IOP contexts. At the other extreme, models
of high IOP and nerve crush have also demonstrated some
reliance on immunomodulation for either protection [19]
or propagation of damage [20].
Cytokine activity is thought to play a substantial part
in anterior chamber changes that can result in elevated
IOP [21, 22]. Interestingly, increased IL-18 within an-
terior chamber structures has been evident even in
young DBA/2J mice before they exhibit elevated IOP [21].
Additionally, increases in IL-6-type cytokines and mem-
bers of the JAK-STAT (Janus kinase signal transducer and
activator of transcription) signaling pathway were shown
in early pressure-induced optic nerve head (ONH) injury
[23]. Microglial release of IL-6 in mixed cultures of RGCs,
microglia, and astrocytes in response to hydrostatic pres-
sure illustrates an important link between cytokine levels
and risk factors for developing glaucoma [24]. Upregula-
tion of genes associated with immune responses (e.g.,
Edn2) have been localized to the retina and ONH of
DBA/2J mice very early on in this disease model, and
therapeutic attempts to block these responses have shown
promise in ameliorating glaucomatous pathology [25].
Previous characterizations of cytokine levels in the context
of glaucoma and related stressors, however, being primar-
ily isolated to portions of the anterior chamber or retina,
fail to tell the entire story regarding inflammatory signal-
ing in glaucomatous neurodegeneration.
Observations of microglial status within the proximal
portion of the RGC projection, in conjunction with cyto-
kine measurements in the eye, suggest that inflammatory
signaling may be an early and ubiquitous dysfunction
that appears prior to clinically diagnosable vision loss.
Therefore, it would be beneficial to assess cytokine levels
throughout the entire RGC projection, especially given
the observation of anterograde transport deficits and dis-
tal axonopathy in glaucoma [4]. Furthermore, elucidat-
ing any relationship between cytokine levels and axonal
transport outcome to the SC is important in moving to-
wards a clinically relevant means of preventing, halting,
or treating the disease. If changes in cytokine signaling
do occur within the RGC projection prior to transport
loss and RGC death, such findings could open the door
for potential therapies that focus on restoring and main-
taining function rather than replacing lost structure or
treating risk factors, such as IOP, in lieu of the actual
mechanisms that drive vision loss.
Methods
Animals
Mixed-sex DBA/2J (n = 32; 10–12 per age group) and
DBA/2J-Gpnmb+ (n = 14; 6–8 per group) mice of different
ages were used for these studies (refer to Table 1 for specific
group nomenclature and group n values). The DBA/2J
mouse has two loss of function mutations that produce iris
atrophy resulting in age-related elevation of IOP and pro-
gressive degeneration of visual structures that mimic hu-
man glaucoma [26]. DBA/2J-Gpnmb+ mice (D2G) have the
same background as DBA/2J mice; however, they express a
functioning wild-type Gpnmb+ allele that prevents them
from developing elevated IOP or glaucomatous pathology
[27]. All animals were originally obtained from The Jackson
Laboratory (Bar Harbor, ME, USA) and were then housed
and aged in the Comparative Medicine Unit at Northeast
Ohio Medical University. As the DBA/2J model has shown
pathological variability in the literature, we based our age
groups for comparison on previous work published by ours
and other lab groups [4, 7, 8, 28] and included the follow-
ing: 3–5-month-old mice (D3–5) representing pre-
glaucomatous ages, 8–10-month-old mice (D8–10) repre-
senting early glaucomatous pathology where anterograde
transport deficits and mild axonopathy are evident, and
12–15-month-old mice (D12–15) representing increasing
transport deficits and axonopathy characteristic of late
glaucomatous pathology [4, 7, 8, 28]. For controls, we used
3–5-month- and 12–15-old D2G mice to represent ages
targeted for pre-glaucomatous and late glaucomatous time
points (G3–5 and G12–15, respectively). Staging of glau-
comatous mice was based on previous work from our
lab as well as others (refer to [4, 7, 28]) and was based







D2G 3–5 months D2Ga 4 8
D2G 12–15 months 4 6
DBA/2J 3–5 months D3–5 5 10
DBA/2J 8–10 months D8–10 6 12
DBA/2J 12–15 months D12–15 5 10
aYoung and old D2G mice were combined into a single control group in order
to simplify results when possible; independent samples t tests indicated that
young and old D2G mice showed few differences in their cytokines levels.
When detected, differences were described within the results section using
G3–5 and G12–15 (referring to young and old D2G mice, respectively)
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on the loss of anterograde and retrograde transport and
eventual RGC loss. We examined all retinas before tissue
preparation to determine that our tracer injections suc-
ceeded and we did not see large-scale loss of RGCs or di-
minished uptake of CTB (Fig. 1). All mice were
maintained in the same housing unit under a 12-h light/
dark cycle with standard rodent chow available ad libitum.
All experimental procedures were approved by the North-
east Ohio Medical University Institutional Animal Care
and Use Committee.
Intravitreal injection of CTB
Animals were anesthetized with 2.5 % isoflurane and
placed prone in a stereotaxic device (Stoelting, Wood
Dale, IL). Cholera toxin B-subunit conjugated to Alexa
Fluor 488 (CTB) was injected into both eyes intravitre-
ally (1.5 μl of 0.1 % CTB in sterile phosphate-buffered
saline (PBS) per eye; Life Technologies: Grand Island, NY)
using a 33-gauge needle attached to a 25 μl Hamilton
syringe. Forty-eight hours later, animals were sacrificed by
decapitation under 2.5 % isoflurane anesthesia.
Microdissection and tissue collection
Retina, ONs, SC, and cerebellum (as a non-glaucomatous
control tissue) were collected and immediately frozen on
dry ice. Whole blood samples were collected in tubes con-
taining 500 mM EDTA on wet ice. ONs were bisected for
analysis of the proximal portion (pON) and distal portion
(dON) separately. Whole-mount SC were imaged using a
Zeiss AxioZoom V16 epifluorescent microscope equipped
with a digital high-resolution camera (AxioCam MRm
Rev.3; Zeiss, Jena, Germany). Under ×16.2 magnification,
SC were microdissected into “transport intact” (i.e., “CTB-
positive”) and “transport absent” (i.e., “CTB-negative”)
samples which were analyzed separately in order to parse
the relationship between transport outcome and protein
levels (Fig. 1). Retinas were flattened and examined to de-
termine success of the tracer injection.
Whole blood samples were centrifuged at 2000×g for
10 min at 4 °C. Supernatants were collected and centri-
fuged for 10 min at 10,000×g and 4 °C. Final supernatant
was used for serum analyses as a control for global
changes in inflammatory markers. Samples were stored at
−80 °C until use.
Fig. 1 Coverage of cholera toxin-B (CTB) transport in the superior colliculus (SC). a–c Whole mount brain (cortex removed) of three mice demonstrating
varying degrees of anterograde transport to major retinal targets that include lateral geniculate nucleus (LGN), pretectum (PT), and SC. a Colliculi
taken from a 12-month-old D2G control mouse show intact axonal transport with full CTB coverage in both right and left SC. b Colliculi taken from a
14-month-old DBA/2J mouse show compromised transport; left SC has 56 % CTB coverage, right SC has 18 % CTB coverage. c Colliculi taken from
12-month-old DBA/2J mouse demonstrate both complete CTB dropout (left SC, 0 % CTB) and complete CTB coverage (right SC, 100 % CTB). Dotted
lines indicate delineation used for microdissections of CTB-negative (i.e., transport absent) areas. d, e Whole mount retinas with successful CTB uptake
via intravitreal injection. f Whole mount SC with areas of transport loss, corresponding to retinas in d and e. Retinal images (d, e) provide evidence that
lack of CTB in SC is not indicative of failed intravitreal injection or lack of CTB uptake
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Tissue processing and multiplex procedure
Tissue samples were rinsed with cold PBS to remove re-
sidual blood. Samples were homogenized via sonication
(10 % amplitude for two 2-s pulses) approximately
200 μl of 0.1 % Igepal Ca-630 detergent dissolved in PBS
with protease inhibitor cocktail (1× Halt Cocktail;
Thermo Fisher, Waltham, MA, USA) and centrifuged at
1000×g for 10 min after which supernatants were col-
lected for further analyses. We obtained 150–230 μg of
protein from each half of the optic nerve and greater than
500 μg protein each from the retina and SC samples.
These amounts were sufficient to perform our bead-based
multiplex assays, so samples were not pooled.
Multiplex assays were conducted in flat-bottom 96-well
plates according to manufacturer’s instructions using re-
agents provided with the kit (Invitrogen Mouse 20-plex
Cytokine Panel, Cat# LMC0006M; Life Technologies:
Grand Island NY, USA). In brief, 50 μl of antibody-
coupled bead solution was pipetted into each well. Sam-
ples were diluted 1:4 in assay diluent to a total volume of
100 μl. One hundred microliters of reconstituted standard
was serially diluted (1:3) and added to appropriate wells.
Fifty microliters of Igepal buffer diluted in 50 μl assay buf-
fer was used as a blank. Finally, 50 μl of incubation buffer
was added to all wells. Plates were kept light-protected
during an overnight incubation (4 °C, 16–18 h) on a titer
plate shaker at 600 rpm.
Following sample incubation, plates were washed with
a mild detergent solution using a magnetic 96-well
separator three times (1 min per wash). One hundred
microliters of horseradish peroxidase-conjugated detec-
tion antibody was added to each well and incubated at
RT for 1 h (shaking at 600 rpm). Plates were washed
three times and 100 μl of streptavidin-rpe was added to
each well. After the 30-min streptavidin-rpe incubation,
plates were again washed three times followed by a final
addition of 125 μl wash solution to all wells. After 3 min
of vigorous shaking, plates were read on a Luminex
Magpix unit (Life Technologies, Grand Island, NY, USA)
and initial analyses were performed by Xponent soft-
ware. Results were exported into Microsoft Excel for fur-
ther processing. Sample size was set to 50 μl, and
minimum count was set to 100 events/bead region.
Bicinchoninic acid assays for total protein concentration
An aliquot of each tissue homogenate was diluted 1:10 in
phosphate buffer, and total protein content was assessed in
tissue samples using bicinchoninic acid (BCA) assay, fol-
lowing manufacturer’s instructions (Cat# 23225, Thermo
Fisher, Waltham, MA, USA). Cytokine levels were all nor-
malized to total protein concentration by dividing cytokine
concentration (pg/ml) by total protein (μg/ml) within each
tissue extract. Samples were not pooled.
FGF-2 immunofluorescence and microscopy
Whole mount retina and retinal cross sections from repre-
sentative animals in each age group, traced with CTB, were
assayed for fibroblast growth factor (FGF)-2 localization.
Since FGF-2 is present at higher levels than most other cyto-
kines, and it showed specific differences between groups in
multiplex analyses, it was chosen for immunostaining to de-
termine if multiplex differences could be supported by
histology.
Tissue was collected from animals given a lethal dose of
sodium pentobarbital (120 mg/kg, ip.) and transcardially
perfused with 4 % paraformaldehyde. The eyes were enucle-
ated and postfixed for 2 h, and then the tissue was placed
in a 20 % sucrose cryoprotectant solution (%w/v in PBS)
prior to dissection. Retina designated for cross-sectioning
were embedded in gelatin, and 10-μm sections were taken
on a cryostat.
Whole retina were assayed as free-floating sections
while cross sections were assayed on slide. The tissues
were blocked with a 5 % normal donkey serum and 1 %
Triton-X 100 in PBS for 2 h. Then, the tissues were incu-
bated for 48 h at 4 °C in the following primary antibody
cocktail (diluted in 3 % serum, 1 % Triton in PBS): rabbit
polyclonal anti-FGF-2 (1:200, Santa Cruz, SC-7911; Dallas,
TX) and mouse monoclonal anti-GFAP (1:500, Millipore,
MAB360; Billerica, MA). Following three 10-min washes
with PBS, secondary antibody cocktail was added for 2 h
at room temperature, which contained donkey anti-rabbit
Alexafluor 594 (1:250, Jackson Laboratories, 711-586-152;
West Grove, PA) and donkey anti-mouse Alexafluor 647
(1:250, Invitrogen, A-31571; Grand Island, NY). The tissue
was then rinsed three times with PBS and mounted and
coverslipped with Fluoromount-G (Southern Biotech,
Birmingham, AL).
Retinas were photographed with a Zeiss Axio Imager M2
epifluorescent microscope equipped with a digital high-
resolution camera (AxioCam MRm Rev.3; Zeiss, Jena
Germany) and a computer-guided motorized X-Y stage. An
apotome module (Zeiss Apotome.2) was used to collect z-
stack of images using structured illumination.
Statistical analyses
Data from XPonent and Excel were imported into IBM
SPSS for Windows 22.0 (IBM Corp., Armonk, NY, USA)
for statistical analysis. Multicolinearity between variables
was observed, necessitating the use of univariate analyses.
In order to compare relationships between the different
cytokines and minimize the skewed distributions, a
log10(x + 1) transformation was used to normalize
data. Results are reported as mean log (cytokine
concentration + 1) ± SEM. The log10(x + 1) was chosen
to minimize negative skewedness that would arise due
to values between 0 and 1 [29].
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Except in the case of distal optic nerve, few differences
between cytokine levels in young and old control D2G
mice were observed by two-tailed, independent samples
t tests. Therefore, to simplify analysis and result presen-
tation, data from these mice were combined into one
D2G control group. In cases where age-dependent ef-
fects were indicated for young and old D2G controls,
these data are either shown graphically or noted within
the results.
One-way analyses of variance (ANOVAs) were used to
test for differences in cytokine levels among groups of
mice categorized by age and strain [D2G, D3–5, D8–10,
D12–15]. Tukey’s honestly significant difference (HSD)
post hoc measures were used to identify specific dif-
ferences between age and strain groups. Separate ana-
lyses were performed for each brain structure (retina,
pON, dON, SC, cerebellum) and serum. Due to multiple
differences observed in dON between G3–5 and G12–15
mice via t tests, subsequent post hoc comparisons sepa-
rated G3–5 and G12–15 groups for analysis. Cytokines in-
cluded in analyses were FGF-2, interleukin-1β (IL-1β),
interleukin-1α (IL-1α), interleukin-10 (IL-10), interleukin-
13 (IL-13), interleukin-6 (IL-6), interleukin-12 (IL-12),
interleukin (IL-17), macrophage inflammatory protein-1α
(MIP-1α), interleukin-5 (IL-5), vascular endothelial
growth factor (VEGF), tumor necrosis factor-α (TNF-α),
interleukin-2 (IL-2), interleukin-4 (IL-4), monokine in-
duced by interferon-γ (MIG), monocyte chemoattractant
protein-1 (MCP-1), keratinocyte chemoattractant (KC),
and interferon-γ (IFN-γ).
For subdivisions of SC based on transport outcome,
ANOVAs were run comparing “CTB-positive” and “CTB-
negative” tissue for the relevant age/strain groups (as antic-
ipated, D3-5 and D2G animals did not have CTB-negative
variables due to intact transport). For purposes of clarity,
graphical representations usually include only those cyto-
kines that showed significant differences between groups.
GM-CSF and IP-10 were eliminated from statistical ana-
lyses due to inconsistent values within and between
groups and low number of structures registering readable
levels of these cytokines. Pearson product-moment correl-
ation coefficients were computed to assess the relationship
between individual cytokine levels in the retina and SC for
each strain and age. Alpha for all tests was set at 0.05.
Results
Early elevations in cytokine levels within the
DBA/2J retina
We found significantly elevated anti-inflammatory
FGF-2 in 8–10-month DBA/2J retinas compared to
D2G controls (F3, 38 = 6.937, p < 0.001), with a trend to-
wards increased FGF-2 in the D12–15 group (p = 0.08).
Anti-inflammatory cytokines IL-5 (F3, 39 = 5.686, p = 0.003)
and IL-10 (F3, 25 = 5.526, p = 0.006) were also elevated in
the retina of D8–10 mice compared to controls. The
following pro-inflammatory cytokines were elevated early in
D3–5 mouse retina compared to controls: VEGF (F3, 39 =
3.098, p = 0.039), IL-12 (F3, 39 = 3.982, p = 0.015), IL-17
(F3, 39 = 3.693, p = 0.020), IL-1α (F3, 36 = 2.924, p = 0.048),
TNF-α (F3, 38 = 3.051, p = 0.041), IFN-γ (F3, 37 = 3.904,
p = 0.017), MIG (F3, 39 = 3.453, p = 0.030), MIP-1α (F3, 30 =
3.255, p = 0.032), and KC (F3, 39 = 6.311, p = 0.009). KC also
remained elevated in the D8-10 retina (p = 0.005) prior to
an age-dependent decrease also observed in other cytokines
(see Fig. 2). Additionally, the following pro-inflammatory
cytokines peaked at 8–10 months of age in DBA/2J retinas,
reaching levels that were significantly greater than D2G
controls: VEGF (F3, 39 = 3.098, p = 0.032), IL-17 (F3, 39 =
3.693, p = 0.034), IL-1α (F3, 36 = 2.924, p = 0.029), TNF-α
(F3, 38 = 3.051, p = 0.029), and IFN-γ (F3, 37 = 3.904, p =
0.033).
No significant differences between old and young D2G
retina were shown for the following cytokines: FGF-2
(t(9) = −2.173, p = 0.058), IL-10 (t(6) = 0.389, p = 0.711),
IL-5 (t(10) = −0.166, p = 0.871), VEGF (t(10) = 0.339,
p = 0.742), IL-12 (t(10) = 1.000, p = 0.341), IL-17 (t(10) =
1.213, p = 0.92), IL-1α (t(10) = 0.552, p = 0.593), TNF-α
(t(10) = −0.411, p = 0.690), IFN-γ (t(9) = −0.333, p = 0.747),
MIG (t(10) = −0.385, p = 0.708), MIP-1α (t(10) = 1.206,
p = 0.255), and KC (t(10) = −0.957, p = 0.361) (data not
shown).
Select pro-inflammatory cytokines are elevated in pON of
DBA/2J mice
Unlike the retina, where cytokines often reached peak
values at D3–5 or D8–10 age groups, cytokines showed
a number of different responses in pON of DBA/2J mice
(Fig. 3). The levels of the anti-inflammatory modulator,
FGF-2, were significantly lower in pON of D3–5 mice
compared to all other groups (F3, 36 = 6.577, p < 0.05).
While the pro-inflammatory cytokine, MIP-1α, was sig-
nificantly lower in pON of D3–5 mice compared to con-
trols (F3, 36 = 4.125, p = 0.009), others showed elevations in
DBA/2J groups compared to controls. Pro-inflammatory
IL-6 was elevated in D12–15 mice compared to controls
and D3–5 mice (F3, 34 = 6.041, p = 0.014). IL-12, on the
other hand, was significantly elevated in D3–5 and D8–10
mice compared to controls and D12–15, which showed
little to no IL-12 in pON (F3, 28 = 3.682, p = 0.026). Finally,
IL-1β was elevated in all DBA/2J groups compared to con-
trols (F3, 15 = 5.948, p = 0.036). (Data are illustrated in
Fig. 3).
No significant differences were seen between old
and young D2G pON in the following cytokines:
FGF-2 (t(10) = −1.921, p = 0.084), IL-1β (t(4) = 1.633,
p = 0.178), IL-6 (t(9) = 0.003, p = 0.998), IL-12 (no IL-12
was detected in D2Gs, so t test not computed), MIP-1α
(t(10) = 0.450, p = 0.662). However, MCP-1 (t(6) = 4.130,
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p = 0.006) and IL-5 (t(9) = 2.871, p = 0.018) were signifi-
cantly reduced in old D2G pON compared to young D2G
pON; MCP-1 showed the opposite trend in DBA/2J pON,
and IL-5 was not significantly different among DBA/2J
pONs across ages. D2G controls were combined since no
differences were shown among cytokines that changed sig-
nificantly for the D2 pON (data not shown).
Age-dependent effects in the distal ON of D2G controls
are absent in DBA/2J mice
Few significant differences were observed in dON among
DBA/2J groups (Fig. 4). Pro-inflammatory IL-1β was ele-
vated in dON of all DBA/2J mice compared to that of
controls (F3, 26 = 3.274, p = 0.039); notably, this pro-
inflammatory cytokine was not detected in D2G mice at
all, but was detected in all DBA/2J groups to some de-
gree. Also, pro-inflammatory MCP-1 was significantly
elevated in D8–10 and D12–15 dON compared to con-
trols (F3, 23 = 3.186, p = 0.046).
Interestingly, unlike other tissue types, the dON showed
a variety of differences between young and old D2G mice.
Therefore, analyses used the separated D2G groups as de-
scribed previously (G3–5 and G12–14), along with D3–5,
D8–10, and D12–15. Pro-inflammatory cytokines and
growth factors that showed a significant elevation in
G12–15 compared to G3–5 mice were as follows:
VEGF (t(10) = 4.025, p = 0.002), MIG (t(9) = 3.572, p = 0.006),
and KC (t(10) = 4.698, p = 0.001). MIP-1α was significantly
Fig. 2 Cytokine protein levels in retina. Anti-inflammatory mediators (FGF-2, IL-10, and IL-5) were elevated in 8–10-month DBA/2J mice and often
demonstrated an age-dependent decrease (a). A number of pro-inflammatory mediators, such as TNF-α, were also elevated in D8–10 mice; others,
such as IL-12 and MIP-1α, were elevated in D3–5, often demonstrating an age-dependent decrease. Error bars depict standard error of the mean.
Asterisk indicates that the group has significantly greater levels than bracketed comparison (p < 0.05). b Photomicrographs depicting CTB (first column)
and elevated immunostaining for FGF-2 (second column) and GFAP (third column) in representative DBA/2J retina whole mount compared to a D2G.
Merged images for all stains are shown in the fourth column. c Photomicrographs of elevated FGF-2 immunostaining in retinal cross sections of
representative DBA/2J compared to D2G. Scale bar = 50 μm
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elevated in G12–15 compared to G3–5 and all DBA/2J
groups (F4, 39 = 7.060, p ≤ 0.009).
Anti-inflammatory cytokines that showed an age-
dependent elevation between G3–5 and G12–15 were
IL-10 (t(6) = 5.831, p = 0.001) and IL-4 (t(10) = 2.576,
p = 0.028). Notably, G12–15 mice had significantly in-
creased anti-inflammatory IL-10 levels compared to DBA/2J
mice of all ages (F4, 29 = 5.107, p = 0.029). (Data are illus-
trated in Fig. 4).
Early increases in pro-inflammatory cytokine levels in the
DBA/2J SC
Early increases in cytokine levels were observed in SC of
DBA/2J mice (without accounting for transport differ-
ences) compared to D2G controls. Anti-inflammatory
modulators IL-4 (F3, 40 = 5.605, p = 0.003) and IL-5 (F3, 41 =
3.713, p = 0.019) were both significantly elevated in
D8–10 mice compared to controls. Pro-inflammatory
modulators, IFN-γ (F3, 31 = 4.352, p = 0.012) and KC
(F3, 42 = 6.035, p = 0.002), were significantly increased
in both D3–5 mice and D8–10 mice compared to D2G.
Pro-inflammatory IL-12 was detected at extremely low
levels in controls and old DBA/2J SC, but in respect to
these values was increased in D8–10 mice and levels
were significantly higher in D3–5 mice (F3, 37 = 5.021,
p = 0.005). (Data are illustrated in Fig. 5).
There were no significant differences between old and
young D2G SC for the majority of cytokines, including
those illustrated (IL-4, IL-5, IL-6 IFN-γ, MIG, IL-12, and
KC). However, pro-inflammatory IL-17 was significantly
Fig. 3 Cytokine protein levels in proximal optic nerve (pON). Anti-inflammatory FGF-2 and pro-inflammatory IL-6 and MIP-1α levels were lower in the
pON of young DBA/2J mice than all other groups. Pro-inflammatory IL-12 was only elevated in pON of young and middle-aged DBA/2J mice. Asterisk
indicates that D3–5 mice have significantly lower cytokine levels than D2G controls and D8–10 and D12–15 pON. Number sign indicates significance
greater than bracketed comparison (p < 0.05). Arrows indicate values below limits of detection for the assay. Error bars depict standard error of
the mean
Fig. 4 Cytokine protein levels in distal optic nerve. For all cytokines shown, with the exception of IL-1β and MCP-1, there was a significant age-dependent
increase in D2G control mice that was not apparent in DBA/2J mice. Pro-inflammatory IL-1β was only detected in DBA/2J mice (arrows indicate values
below the detection limit of assay). Asterisk indicates that the group has significantly higher levels than bracketed comparisons (p < 0.05). Error bars
show the standard error of the mean
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reduced in old D2G SC compared to young D2G co-
horts (t(10) = 3.820, p = 0.003; data not shown).
IL-6 is the only cytokine that demonstrates a relationship
to axonal transport outcome
Most cytokines did not differ based on anterograde
transport outcome of CTB; however, IL-6 was an
exception. IL-6 levels were significantly increased in
transport-absent SC compared to transport-intact SC
(F5, 31 = 5.543, p = 0.001; Fig. 6). This finding is of particu-
lar interest because elevation of IL-6 was not apparent
when analyzing the SC data before segregation of samples
based on transport outcome.
Cerebellum
No significant differences in cerebellar cytokine levels
were observed in DBA/2J and D2G mice across ages
(Table 2) indicating that differences in cytokine levels are
not generalizable to the nervous system in these mice.
Serum
There were no differences between DBA/2J and D2G
serum levels of cytokines, indicating that changes observed
in visual system tissues were not globally present. Cytokine
measurements in serum showed much higher inter-
sample variability than cytokine levels in the other tissue
analyzed in this study.
Relationship between retina and SC cytokine levels
Given the frequent disconnect between pathology in
the retina versus targets in the brain, we sought to
identify any relationships in cytokine levels between
these two structures. Few cytokines showed a strong
and consistent relationship between retinal and col-
licular levels (p > 0.05). However, FGF-2 levels in the
retina and SC were significantly correlated in our
youngest D2G and DBA/2J mice [Fig. 7, G3–5
(r2 = 0.887, p = 0.018); D3–5 (r2 = 0.849, p = 0.016)].
This relationship was not reflected in older animals of ei-
ther strain. This finding suggests that age, independent of
pathology, may disrupt the association between retinal
and collicular FGF-2 levels in mice. Pathological changes
may further challenge this relationship, as we observed
Fig. 5 Cytokine protein levels in superior colliculus (SC). Anti-inflammatory IL-4 and IL-5 were elevated in D8–10 mice, while pro-inflammatory
IFN-γ and KC were elevated in D3–5 and D8–10 DBA/2J mice compared to controls. Pro-inflammatory IL-12 levels were increased in D3–5 DBA/2J
mice compared to controls and 12–15 DBA/2J mice. Arrows indicate levels below the detection limit of the assay. Asterisk indicates that the group
has significantly higher levels than bracketed comparisons (p < 0.05). Error bars indicate the standard error of the mean
Fig. 6 IL-6 levels based on age, strain, and CTB transport to the
superior colliculus (SC). Differences in collicular IL-6 levels emerged
in 12–15-month-old mice based on transport outcome, with transport
absent regions (CTB−) demonstrating significantly greater IL-6 than
transport intact (CTB+) regions (asterisk indicates p < 0.05). There is no
anticipated loss of transport in controls and D3–5-month-old groups.
Error bars show standard error of the mean
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elevations in absolute retinal FGF-2 levels in DBA/2J mice
compared to controls (see Fig. 2).
Additionally, IL-6 retinal and collicular levels in young
D2G mice were positively correlated, and there was a
trend towards this effect in the oldest D2G mice [G3–5
(r2 = 0.961, p = 0.009); G12–15 (r2 = 0.736, p = 0.08)]. No
such relationships between retinal and collicular IL-6
levels were shown in any DBA/2J group (Fig. 8). The ab-
sence of this relationship in DBA/2J mice at any age indi-
cates that there may be an early and sustained disruption
in the association of retinal and collicular IL-6.
FGF-2 immunofluorescence
Cross sectioned and whole retina show a clear distinc-
tion in FGF-2 levels between D2G and DBA/2J groups,
with all DBA/2J groups demonstrating increased FGF-2
immunoreactivity (Fig. 2), which supports multiplex data
from the retina. The distinction between DBA/2J groups
illustrated by multiplex analyses, however, is not as ap-
parent in histological sections. Inner and outer plexiform
layers are most densely stained for FGF-2, with diffuse
staining throughout other layers of the retina. Data illus-
trates that the retinal ganglion cell layer is not the only
location of FGF-2, and therefore, the FGF-2 detected by
multiplex analyses is mostly due to its concentration in
these other layers. This also suggests that glia and other
cell types constitute the majority of FGF-2 production in
the retina. Müller glia are likely a major producer of
FGF-2 as reported by Hageman and colleagues [30] and
others (refer to [31, 32]).
Discussion
Glaucoma is an age-related degenerative disorder in
which microglial abnormalities have been described, es-
pecially at the optic nerve head and retina [18, 33]. Spe-
cifically, microglia are found in activated, ramified
clusters within the glaucomatous optic nerve head [33].
However, despite the initial changes to ONH, we have
previously reported that pathology, presumably due to
these changes, manifests distally in retinal targets such
as SC [4]. This disparity between locations of the stres-
sor and manifestation of pathology is commonly seen in
neurodegenerative disorders [34]. Despite this pattern of
progression, a comprehensive description of cytokine
profiles throughout this projection apart from retina and
optic nerve head has not been done. Our work provides
an age-dependent analysis of cytokine levels throughout
the entire retinal projection of the glaucomatous DBA/2J
model with respect to functional outcome.
Cytokine protein levels along RGC projection with age
and pathology
Early elevations of classically categorized pro-inflammatory
cytokines—specifically IFNγ, MIG, KC, TNF-α, and
Table 2 Cerebellar cytokine levels across age and strain












FGF-2 574.40 20.60 562.70 30.40 452.60 12.30 473.30 122.50 531.30 57.20
IFN-γ 2.20 0.90 2.00 1.00 1.80 0.90 6.30 2.90 2.20 1.80
IL-1α 2.50 0.30 1.20 0.30 1.80 0.90 4.40 1.80 2.90 1.60
IL-1β 2.60 0.80 16.80 12.50 7.20 6.20 7.10 3.90 9.60 5.20
IL-2 2.30 0.60 2.50 0.30 1.10 0.60 4.40 2.90 3.10 1.70
IL-4 6.77 5.90 27.50 0.10 21.50 14.00 3.00 0.00 23.80 20.90
IL-5 1.66 0.68 1.80 0.56 3.60 0.91 4.56 2.10 3.01 1.17
IL-6 9.80 1.80 8.70 0.30 5.10 0.80 10.60 4.50 8.70 3.40
IL-10 1.60 0.20 14.60 3.80 8.20 6.00 30.10 27.90 26.80 23.70
IL-13 3.10 3.10 7.90 7.90 2.60 0.90 12.60 7.30 9.87 5.00
IL-12 – – – – 3.30 1.90 0.90 0.90 – –
IL-17 0.20 0.03 0.04 0.02 0.04 0.01 0.30 0.10 0.20 0.09
KC 215.55 32.76 99.25 67.50 133.07 63.85 268.06 66.14 199.67 60.04
MCP-1 N/A N/A – – – – 1.90 1.90 1.35 0.69
MIG 86.96 19.48 10.40 2.40 11.73 2.72 12.98 4.86 12.09 4.64
MIP-1α 10.10 0.30 7.80 0.10 9.18 0.60 14.43 5.20 10.30 2.95
TNF-α 0.72 0.72 1.20 0.46 11.70 6.35 1.48 1.48 1.72 1.72
En dashes indicate that all values were below the limit of detection; for such cases, a zero was recorded. N/A indicates that the majority of samples had no
reading or an error reading, which is distinguished from a reading that is simply below the limit of detection
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MIP-1α—observed in the retina and SC may signal
the progression of pathological changes in the visual pro-
jection of DBA/2J mice prior to functional transport loss
and RGC death. While the majority of changes we ob-
served were in pro-inflammatory mediators, our results
suggest that anti-inflammatory cytokines may play a com-
pensatory role early in glaucoma prior to transport loss, as
evidenced by early elevations in retinal IL-5 and IL-10.
Other work has shown that IL-10 plays a role in RGC
survival and IL-5 has similar functions [35].
TNF-α is another important pro-inflammatory cyto-
kine that was found to be upregulated in the retina of
8–10-month DBA/2J mice, which is expected given that
TNF-α has cytotoxic effects associated with apoptotic
signaling [36]. In support of our findings, recent work
has shown that TNF-α may actually be protective early
in glaucomatous pathology, as TNF-α expression is up-
regulated immediately following nerve crush and TNF-α
deficiency intensifies RGC injury following nerve crush
[19]. Previous work from other laboratories has shown
increased immunolabeling of TNF-α and its associated
death receptor, TNF-R1, in the optic nerve head and ret-
ina of glaucomatous human donor eyes [37, 38]. While
TNF-α was upregulated primarily in glia of retina and
optic nerve head, the TNF-1R was most prominent in
RGC bodies, suggesting that RGCs may be especially
susceptible to the effects of TNF-α [37, 38]. Conversely,
TNF-α has also been shown to have early neuroprotec-
tive effects via actions of the less-prominent TNF-R2.
While some RGC death can be observed in the 8–10-
month DBA/2J retina, the protective effects associated with
TNF-R2 may be why there is a temporal delay between ob-
served TNF-α elevations and the age at which RGC death
becomes overwhelmingly significant (13–15 months; refer
to [7]).
Additionally, FGF-2 upregulation was shown in the
retina of 8–10-month-old DBA/2J mice (with trends to-
wards this elevation in D3–5 and D12–15 groups), sug-
gesting that FGF-2 may be an early signal of cellular
stress. Recently, the Noda laboratory described the re-
sponse of microglia to FGF-2 with experiments that
demonstrated that (a) degenerating neurons released
FGF-2 and that (b) microglia specifically responded to
this FGF-2 release by adopting an amoeboid phenotype
and migrating towards FGF-2 at sites of neuronal degen-
eration [39]. In our studies, FGF-2 levels in retina and
SC of young D2G mice were similar, but became disso-
ciated in older D2Gs. This age-dependent pattern of
FGF-2 expression in the retina and SC was recapitu-
lated in DBA/2J mice, but their overall FGF-2 levels
were an order of magnitude above those of the D2G
controls. Therefore, while FGF-2 levels may become
Fig. 8 Scatterplot showing relationship between retinal and collicular
IL-6. Symbols represent individual retina versus the corresponding
superior colliculus. A significant, positive correlation between retinal
and collicular IL-6 levels in young D2G mice (Pearson’s r2) and a strong
trend towards this same relationship was indicated in old D2G mice.
Regression lines have been drawn for each of these groups to illustrate
relationships. No significant relationships were shown for other groups.
p values are indicated on figure
Fig. 7 Scatterplot showing relationship between retinal and collicular
FGF-2 levels. Symbols represent individual retina versus the
corresponding superior colliculus. Significant positive correlations were
indicated between retinal and collicular FGF-2 levels for both young
D2G (3–5 months) and young DBA/2J (3–5 months) mice (Pearson’s r2).
Regression lines have been drawn for each of these groups to
illustrate these relationships. No significant relationships were
shown for other groups, including aged D2G mice. p values are
indicated on the figure
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deregulated between the retina and SC as a feature of
normal aging, it is likely that the actual magnitude of con-
centrations and not the relative values between structures
are the important factor in DBA/2J pathology.
Immunostaining in the retina also supported multiplex
FGF-2 data overall, showing an increase in the DBA/2J
retina compared to D2G controls. It is noteworthy that
FGF-2 expression was apparent in several layers, specif-
ically the outer and inner plexiform layers of the retina
and not just in ganglion cells; this is relevant since the
whole retina was analyzed in the multiplexing experi-
ments. FGF-2 is produced by a variety of cell types in-
cluding Müller glia, RGCs, and other cell types [30, 31].
Furthermore, FGF-2 stimulates Müller cell proliferation
[32]. Wen and colleagues also showed that FGF-2 is upreg-
ulated in the retina in response to acute, mechanical injury
and suggested that this actually serves as a protective re-
sponse in the context of photoreceptor degeneration [31].
While chronic, glaucomatous neurodegeneration differs
distinctly from this acute type of photoreceptor degener-
ation, it is still a logical extrapolation that our observed
FGF-2 elevations within DBA/2J retina could be an intrin-
sic signal or attempt to by retinal cells to be “rescued.”
While FGF-2 elevations and other anti-inflammatory
changes in the SC did differ significantly between DBA/2J
age groups, anti-inflammatory IL-4 and IL-5 were elevated
in the D8–10 age group. Additionally, a number of pro-
inflammatory cytokines were elevated in young DBA/2J
mice compared to D2G mice and older DBA/2J mice. For
example, KC was elevated in all D3–5 and D8–10 groups
compared to D2G mice, which may drive some of the
more prolonged inflammation and advanced pathology
within the DBA/2J strain. This idea is supported by data
in htau mice, a common neurodegenerative model for
Alzheimer’s disease, which show elevated KC and MIG,
among other pro-inflammatory mediators, within their
cortex when compared to controls [40]. Other pro-
inflammatory cytokines elevated in D3–5 SC included
IL-12 and IFN-γ, which may also perpetuate early path-
ology prior to transport loss.
Interestingly, distal portions of the ON in control mice
showed age-dependent elevations in cytokines—a finding
that was absent in aging DBA/2J mice and contrasted
with findings in other regions of the visual projection.
Some notable changes in dON of D2G mice with age
were in levels of anti-inflammatory cytokines IL-10, and
IL-4, suggesting that these may be protective elevations
that occur in the distal projection of the ON during nor-
mal aging. This was corroborated by the finding that
DBA/2J mice lacked this response as they aged.
Notably, IL-1β was significantly elevated in both prox-
imal and distal portions of the optic nerve in DBA/2J
mice compared to controls, indicating a possible role for
this cytokine in distal axonopathy in glaucoma [4]. IL-1β
has been shown to be an upstream activator of JNK via
transforming growth factor-β activating kinase-1 (TAK1)
[41], and hyperphosphorylation of neurofilaments and
motor proteins by JNK may alter the substrate and ma-
chinery by which axonal transport occurs to sustain cel-
lular and axonal viability [42].
Cytokines and axonal transport
Largely, changes in cytokine levels were independent of
axonal transport outcome in the SC as well as in the
corresponding retina. However, due to the small sample
size and variability within the DBA/2J strain, these data
should be interpreted cautiously. Interestingly, IL-6 was
the only molecule that differed based on transport out-
come; as expected, IL-6 levels were highest in the most
pathological (i.e., transport-absent) SC at 12–15 months.
Given that RGC death in DBA/2J mice occurs most
significantly at 18 months of age [28] and D8–10 SC
showed no differences in IL-6 based on transport, in-
creased IL-6 in transport-deficient SC of D12–15 mice
may signal impending RGC loss. This contrasts with
reports in the retina, which has shown that an IL-6
transducer was elevated under conditions of glaucoma-
related stress before RGC loss [43].
The function of IL-6 in these regions has been suggested
to be involved in the regeneration of injured axons in optic
nerve trauma and more acute IOP elevation [44]. The
chronic degeneration in DBA/2J mice, however, presents a
more complicated scenario. While IL-6 levels were signifi-
cantly reduced in the proximal optic nerve of DBA/2J
mice compared to controls, possibly due to transport defi-
cits, these levels increased with age and were significantly
greater in the SC of the oldest DBA/2J groups. Given that
we do not see extensive axon injury until then [4, 7, 8, 28],
elevation of IL-6 within the D12-15 SC suggests that this
signaling may be a neuroprotective mechanism attempting
to salvage or replace lost connections [44].
We observed that IL-6 levels were highly correlated
between the retina and SC of young D2G mice, and
there was a trend toward this relationship in the old
D2G controls. However, in DBA/2J mice, we did not see
a relationship between retinal and collicular IL-6. As has
been suggested previously [44], IL-6 may be elevated
specifically in response to axon damage. Given that we
have previously reported distal axonopathy in this
model, we would expect elevations in IL-6 to occur in
the distal targets (e.g., SC) first, therefore uncoupling the
relationship between retina and SC.
Conclusion
Dysregulation of cytokine signaling throughout the RGC
projection of DBA/2J mice is evident early in pathology.
Early elevations of classic pro-inflammatory cytokines in
the retina—specifically IFNγ, MIG, KC, TNF-α, and
Wilson et al. Journal of Neuroinflammation  (2015) 12:176 Page 11 of 13
MIP-1α as well as consistent elevations in IL-1β through-
out the ON may signal the progression of pathological
changes in the visual projection of DBA/2J mice prior to
functional transport loss and RGC death. Additionally,
differences in cytokine levels, either age-related or strain-
related, are compartmentalized throughout the RGC pro-
jection. Overall, DBA/2J mice show many age-dependent
changes in pro-inflammatory cytokines and some alter-
ations in anti-inflammatory cytokines that are not observed
in control mice within the retina and proximal ON and SC.
Our data suggest that changes in cytokine and growth
factor levels may occur prior to functional transport loss
and are consistent with previous work showing inflam-
matory changes and immune-mediated vasoconstriction
early in glaucomatous pathology [25]. Such alterations in
immunomodulatory molecules may be among the subtle
changes that occur prior to overt cytoskeletal damage,
loss of axonal transport, and cell death. However, IL-6
levels were elevated in accordance with axonal transport
loss in our oldest DBA/2J mice, indicating that IL-6 may
be a reliable marker of late pathological states [44]. Pre-
vious work by Luterman and colleagues [45] showed a
similar pattern in patients with late/terminal Alzheimer’s
disease exhibiting greater amounts of IL-6 mRNA in
entorhinal cortex and temporal gyrus compared to con-
trols. This group also demonstrated that levels of IL-6
were positively correlated with neurofibrillary tangles
[45]. Thus, IL-6 elevations in the SC may be closely
coupled to structural demise and axonal loss, as previous
work from our lab has shown that both retrograde trans-
port deficits and structural loss are characteristic of the
12–15-month DBA/2J group [7]. However, the current
study did not directly assess this relationship.
Given that our findings indicate a complex role for cyto-
kine signaling throughout the RGC projection, it would be
interesting to parse out immune cell phenotypes respon-
sible for cytokine release versus resting, phagocytotic,
primed, or senescent phenotypes throughout the projec-
tion as a function of strain and age. Additionally, further
investigation into the interplay between the immune sys-
tem and axonal transport disruption via downstream,
kinase-mediated cytoskeletal, or motor protein modifica-
tions could also provide important insight into the pro-
gression and potential therapeutic targets of glaucoma
and other related neurodegenerations.
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